Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia

Psychological Medicine
A K Martin, Bryan J Mowry

Abstract

A significant number of patients with schizophrenia fail to respond to antipsychotic medication. Although several studies have investigated associated patient characteristics, the emerging findings from genetic studies offer further scope for study. In 612 schizophrenia patients with detailed clinical information, common genetic variants indexed by polygenic risk scores, and rare variants indexed by deletion and duplication burden genomewide, we explored potential genetic predictors alongside other established risk factors for treatment resistance. Clinical outcomes of treatment resistance were also calculated using lifetime measures of positive, negative/disorganized and mood symptoms as well as number of hospitalizations and suicide attempts. Logistic regression models identified a significant relationship between treatment resistance and total duplication burden genomewide, years of formal schooling and age at onset. Clinically, treatment-resistant patients were characterized by greater negative/disorganized and positive symptoms and greater number of hospitalizations. Taken together, these findings suggest genetic information, specifically the genomewide burden of rare copy number variants, may increase our understanding an...Continue Reading

References

May 1, 1993·Archives of General Psychiatry·J LiebermanM Borenstein
May 1, 1996·Schizophrenia Research·S GuptaE A Haffke
Apr 29, 1998·Journal of Clinical Psychopharmacology·R M Murray, J Van Os
May 17, 2000·American Journal of Medical Genetics·A G Cardno, I I Gottesman
Jun 1, 2000·The American Journal of Psychiatry·D MalaspinaJ M Gorman
Jan 18, 2006·Advances in Chronic Kidney Disease·Brent W Miller
Feb 29, 2008·Child and Adolescent Psychiatry and Mental Health·Andreas ReichertAndreas Warnke
Jun 25, 2008·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vita DolzanBlanka Kores Plesnicar
Dec 18, 2010·Expert Opinion on Drug Metabolism & Toxicology·Jian-Ping Zhang, Anil K Malhotra
Aug 29, 2012·Journal of Clinical Psychopharmacology·Jimmi NielsenChristoph U Correll
Dec 6, 2012·The American Journal of Psychiatry·Ayman H FanousUNKNOWN Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium
Feb 23, 2013·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Rebecca SchennachHans-Jürgen Möller
Feb 26, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Benedicto Crespo-FacorroJosé Luis Vázquez-Barquero
Apr 2, 2014·Schizophrenia Research·Andrew Kenneth MartinBryan Mowry
Apr 29, 2014·Schizophrenia Research·Ronald A YeoVince D Calhoun
Jul 25, 2014·Nature·UNKNOWN Schizophrenia Working Group of the Psychiatric Genomics Consortium
Aug 19, 2014·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Naomi R WrayChristel M Middeldorp
Dec 4, 2014·Schizophrenia Research·Ahmed N Hassan, Vincenzo De Luca
May 7, 2015·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Andrew K MartinBryan Mowry

❮ Previous
Next ❯

Citations

Jun 18, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Andrea SchmittUNKNOWN WFSBP Task Force on Biological Markers
Jul 12, 2017·Biological Research for Nursing·Rose Mary Xavier, Allison Vorderstrasse
May 2, 2019·Frontiers in Pharmacology·Antonio VitaMassimo Gennarelli
Jun 14, 2019·Frontiers in Pharmacology·Claudia Pisanu, Alessio Squassina
Feb 12, 2017·Schizophrenia Bulletin·Theresa WimberleyHenriette Thisted Horsdal
Jun 28, 2017·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Frederick C NuciforaAkira Sawa
Jun 4, 2019·The British Journal of Psychiatry : the Journal of Mental Science·Sophie E LeggeJames T R Walters

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here